Literature DB >> 19252282

The Chinese prescription Wen-Pi-Tang extract delays disease onset in amyotrophic lateral sclerosis model mice while attenuating the activation of glial cells in the spinal cord.

Michiko Sekiya1, Takashi Ichiyanagi, Yasumasa Ikeshiro, Takako Yokozawa.   

Abstract

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the selective loss of motor neurons. There is no effective treatment or drug against ALS, and the precise mechanisms leading to the selective loss of motor neurons are still unknown. We investigated the effect of a Chinese prescription, Wen-Pi-Tang, on the ALS model mouse SOD1(G93A). Although the oral administration of Wen-Pi-Tang extract to SOD1(G93A) mice had no significant effect on body weight loss and survival time, Wen-Pi-Tang delayed disease onset. Therefore, we evaluated immunohistological changes in the spinal cord of SOD1(G93A) mice during the early disease period, and found that Wen-Pi-Tang extract inhibited neuronal loss in the lumbar segment of the spinal cord of mice. Furthermore, increased astrocytes and microglial cells, which increase prior to neuronal loss, in spinal cords were significantly reduced in the Wen-Pi-Tang treated group. Since oxidative markers, heme oxygenase-1 and inducible nitric oxide synthase, in the spinal cord were also reduced as well as the change in microglia, the administration of Wen-Pi-Tang was thought to delay disease onset by inhibiting glial cell activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252282     DOI: 10.1248/bpb.32.382

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Dietary supplementation with S-adenosyl methionine delays the onset of motor neuron pathology in a murine model of amyotrophic lateral sclerosis.

Authors:  James Suchy; Sangmook Lee; Ambar Ahmed; Thomas B Shea
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

2.  One universal common endpoint in mouse models of amyotrophic lateral sclerosis.

Authors:  Jesse A Solomon; Mark A Tarnopolsky; Mazen J Hamadeh
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

3.  Type I Vs. Type II Cytokine Levels as a Function of SOD1 G93A Mouse Amyotrophic Lateral Sclerosis Disease Progression.

Authors:  Amilia Jeyachandran; Benjamin Mertens; Eric A McKissick; Cassie S Mitchell
Journal:  Front Cell Neurosci       Date:  2015-12-01       Impact factor: 5.505

4.  A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy.

Authors:  Leila Bond; Kamren Bernhardt; Priyank Madria; Katherine Sorrentino; Hailee Scelsi; Cassie S Mitchell
Journal:  Front Neurosci       Date:  2018-01-24       Impact factor: 4.677

Review 5.  Traditional Korean Medicine Treatment for Patients with Wilting Disorder: A Literature Review of In Vivo Studies.

Authors:  Sung-Jin Kim; Yeon-Cheol Park; Yong-Hyeon Baek; Byung-Kwan Seo
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-13       Impact factor: 2.629

6.  Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis.

Authors:  Stephen R Pfohl; Martin T Halicek; Cassie S Mitchell
Journal:  J Neuromuscul Dis       Date:  2015-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.